Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
000806.SZ Stock Summary
In the News
000806.SZ Financial details
Company Rating
Sell
Market Cap
461.96M
Income
-395.78M
Revenue
1.45B
Book val./share
-1.21
Cash/share
0.06
Dividend
-
Dividend %
-
Employees
2.03K
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-1.17
Forward P/E
-
PEG
0.2
P/S
0.32
P/B
-0.35
P/C
-
P/FCF
-1.15
Quick Ratio
1.16
Current Ratio
1.4
Debt / Equity
-0.16
LT Debt / Equity
-0.01
-
-
EPS (TTM)
-0.36
EPS next Y
-
EPS next Q
-
EPS this Y
-64.77%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-13.5%
Revenue last 5Y
14.95%
Revenue Q/Q
-37.2%
EPS Q/Q
-74.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-20%
ROE
36%
ROC
-0.21%
Gross Margin
35%
Oper. Margin
-14%
Profit Margin
-27%
Payout
-3%
Shs Outstand
1.1B
Shs Float
0
-
-
-
-
Target Price
-
52W Range
0.39-2.62
52W High
-
52W Low
-
RSI
-
Rel Volume
3.85
Avg Volume
8.81M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.263907
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
000806.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.69 | 0.71 | 1.01 | 1.04 | 1.39 | |
Net income per share | -0.64 | -1.26 | 0.05 | -0.88 | -0.31 | |
Operating cash flow per share | -0.33 | 0.06 | 0.04 | -0.02 | -0.03 | |
Free cash flow per share | -0.34 | 0.05 | 0.02 | -0.04 | -0.04 | |
Cash per share | 0 | 0.04 | 0.12 | 0.02 | 0.07 | |
Book value per share | 1.26 | 0.02 | 0.06 | -0.81 | -1.14 | |
Tangible book value per share | 1.15 | -0.1 | -0.05 | -0.92 | -1.23 | |
Share holders equity per share | 1.26 | 0.02 | 0.06 | -0.81 | -1.14 | |
Interest debt per share | 0.54 | 0.22 | 0.16 | 0.12 | 0.2 | |
Market cap | 4.36B | 2.49B | 1.84B | 2.91B | 1.94B | |
Enterprise value | 4.84B | 2.57B | 1.89B | 2.95B | 2.06B | |
P/E ratio | -6.17 | -1.8 | 31.51 | -3.01 | -5.75 | |
Price to sales ratio | 5.72 | 3.18 | 1.66 | 2.55 | 1.27 | |
POCF ratio | -11.96 | 39.33 | 41.11 | -106.93 | -56.9 | |
PFCF ratio | -11.52 | 48.02 | 70.5 | -59.11 | -47.22 | |
P/B Ratio | 3.14 | 103.17 | 27.46 | -3.29 | -1.54 | |
PTB ratio | 3.14 | 103.17 | 27.46 | -3.29 | -1.54 | |
EV to sales | 6.35 | 3.29 | 1.71 | 2.58 | 1.35 | |
Enterprise value over EBITDA | -28.15 | -8.1 | 13.67 | 27.49 | 7.74 | |
EV to operating cash flow | -13.27 | 40.63 | 42.2 | -108.22 | -60.44 | |
EV to free cash flow | -12.78 | 49.6 | 72.36 | -59.83 | -50.16 | |
Earnings yield | -0.16 | -0.56 | 0.03 | -0.33 | -0.17 | |
Free cash flow yield | -0.09 | 0.02 | 0.01 | -0.02 | -0.02 | |
Debt to equity | 0.38 | 7.56 | 2.37 | -0.14 | -0.16 | |
Debt to assets | 0.21 | 0.11 | 0.07 | 0.07 | 0.1 | |
Net debt to EBITDA | -2.79 | -0.26 | 0.35 | 0.33 | 0.45 | |
Current ratio | 1.66 | 0.88 | 1.33 | 1.41 | 1.4 | |
Interest coverage | -10.85 | -1.65 | 5.44 | 4.12 | 11.56 | |
Income quality | 0.49 | -0.05 | 0.72 | 0.03 | 0.1 | |
Dividend Yield | 0.01 | 0.01 | 0 | 0 | 0 | |
Payout ratio | -0.05 | -0.01 | 0.14 | 0 | -0.01 | |
Sales general and administrative to revenue | 0.08 | 0.07 | 0.03 | 0.07 | 0.02 | |
Research and developement to revenue | 0.13 | 0.05 | 0.03 | 0.05 | 0.05 | |
Intangibles to total assets | 0.05 | 0.07 | 0.06 | 0.07 | 0.06 | |
Capex to operating cash flow | 0.04 | -0.18 | -0.42 | 0.81 | 0.21 | |
Capex to revenue | -0.02 | -0.01 | -0.02 | -0.02 | 0 | |
Capex to depreciation | -0.31 | -0.36 | -0.66 | -0.46 | -0.15 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 4.27 | 0.79 | 0.27 | 3.99 | 2.8 | |
ROIC | -0.39 | -0.52 | 0.36 | -0.08 | -0.23 | |
Return on tangible assets | -0.3 | -0.87 | 0.03 | -0.6 | -0.18 | |
Graham Net | 0.07 | -0.91 | -0.87 | -1.73 | -1.99 | |
Working capital | 679.55M | -150.8M | 380.85M | 331.4M | 419.22M | |
Tangible asset value | 1.26B | -106.98M | -58.64M | -1.01B | -1.36B | |
Net current asset value | 624.6M | -636.27M | -543.95M | -1.5B | -1.79B | |
Invested capital | 0.38 | 7.56 | 2.37 | -0.14 | -0.16 | |
Average receivables | 1.31B | 1.06B | 921.13M | 952.79M | 968.42M | |
Average payables | 280.48M | 302.77M | 321.94M | 282.54M | 273.18M | |
Average inventory | 356.46M | 244.87M | 246.48M | 256.97M | 240.06M | |
Days sales outstanding | 678.04 | 325.13 | 378.27 | 242.27 | 281.26 | |
Days payables outstanding | 160.61 | 218.8 | 153.99 | 132.62 | 105.7 | |
Days of inventory on hand | 139.14 | 167.11 | 118.21 | 142.53 | 73.95 | |
Receivables turnover | 0.54 | 1.12 | 0.96 | 1.51 | 1.3 | |
Payables turnover | 2.27 | 1.67 | 2.37 | 2.75 | 3.45 | |
Inventory turnover | 2.62 | 2.18 | 3.09 | 2.56 | 4.94 | |
ROE | -0.51 | -57.39 | 0.87 | 1.09 | 0.27 | |
Capex per share | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.29 | 0.41 | 0.32 | 0.36 | 0.22 | |
Net income per share | -0.01 | 0.01 | -0.04 | -0.26 | -0.07 | |
Operating cash flow per share | -0.03 | 0.01 | -0.04 | -0.26 | -0.07 | |
Free cash flow per share | -0.03 | 0.01 | -0.04 | -0.26 | -0.07 | |
Cash per share | 0.06 | 0.05 | 0.05 | 0.07 | 0.06 | |
Book value per share | -0.82 | -0.83 | -0.87 | -1.14 | -1.21 | |
Tangible book value per share | -0.93 | -0.92 | -0.96 | -1.23 | -1.3 | |
Share holders equity per share | -0.82 | -0.83 | -0.87 | -1.14 | -1.21 | |
Interest debt per share | 0.11 | 0.12 | 0.12 | 0.19 | 0.2 | |
Market cap | 2.25B | 2.48B | 2.33B | 1.94B | 1.26B | |
Enterprise value | 2.31B | 2.55B | 2.4B | 2.06B | 1.41B | |
P/E ratio | -39.61 | 71.59 | -13.65 | -1.67 | -4.34 | |
Price to sales ratio | 6.99 | 5.42 | 6.54 | 4.94 | 5.13 | |
POCF ratio | -70.14 | 286.38 | -54.58 | -6.7 | -17.34 | |
PFCF ratio | -66.73 | 382.56 | -52.76 | -6.66 | -17.14 | |
P/B Ratio | -2.5 | -2.72 | -2.43 | -1.54 | -0.95 | |
PTB ratio | -2.5 | -2.72 | -2.43 | -1.54 | -0.95 | |
EV to sales | 7.16 | 5.58 | 6.75 | 5.24 | 5.73 | |
Enterprise value over EBITDA | 45.8 | 27.99 | 45.74 | 83.83 | 133.22 | |
EV to operating cash flow | -71.87 | 294.57 | -56.31 | -7.12 | -19.37 | |
EV to free cash flow | -68.38 | 393.5 | -54.43 | -7.08 | -19.15 | |
Earnings yield | -0.01 | 0 | -0.02 | -0.15 | -0.06 | |
Free cash flow yield | -0.01 | 0 | -0.02 | -0.15 | -0.06 | |
Debt to equity | -0.13 | -0.14 | -0.13 | -0.16 | -0.16 | |
Debt to assets | 0.07 | 0.07 | 0.07 | 0.1 | 0.11 | |
Net debt to EBITDA | 1.11 | 0.78 | 1.4 | 4.91 | 13.99 | |
Current ratio | 1.41 | 1.43 | 1.46 | 1.4 | 1.4 | |
Interest coverage | 17.28 | 20.49 | 12.22 | -37.23 | -14.58 | |
Income quality | 2.19 | 1 | 1 | 1 | 1 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.14 | 0.21 | -0.12 | -0.01 | -0.04 | |
Sales general and administrative to revenue | 0.1 | -0.04 | 0.23 | -0.15 | 0.14 | |
Research and developement to revenue | 0.04 | 0.03 | 0.03 | 0.08 | 0.06 | |
Intangibles to total assets | 0.07 | 0.07 | 0.06 | 0.06 | 0.06 | |
Capex to operating cash flow | 0.05 | -0.25 | 0.03 | 0.01 | 0.01 | |
Capex to revenue | -0.01 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.49 | 0.38 | 0.87 | 2.6 | 1.34 | |
ROIC | -0.17 | -0.05 | -0.08 | 0.27 | 0.06 | |
Return on tangible assets | -0.01 | 0.01 | -0.03 | -0.15 | -0.04 | |
Graham Net | -1.66 | -1.65 | -1.69 | -1.99 | -2.07 | |
Working capital | 319.11M | 352.02M | 391.14M | 419.22M | 421.73M | |
Tangible asset value | -1.02B | -1.02B | -1.06B | -1.36B | -1.43B | |
Net current asset value | -1.51B | -1.49B | -1.51B | -1.79B | -1.86B | |
Invested capital | -0.13 | -0.14 | -0.13 | -0.16 | -0.16 | |
Average receivables | 764.02M | 831.22M | 924.05M | 1.07B | 1.16B | |
Average payables | 250.92M | 246.62M | 254.99M | 271.47M | 292.14M | |
Average inventory | 271.1M | 235.22M | 222.06M | 217.5M | 225.61M | |
Days sales outstanding | 214.84 | 175.72 | 241.22 | 270.22 | 417.08 | |
Days payables outstanding | 103.76 | 76.23 | 103.41 | 101 | 159.75 | |
Days of inventory on hand | 112.74 | 63.04 | 94.5 | 70.65 | 134.46 | |
Receivables turnover | 0.42 | 0.51 | 0.37 | 0.33 | 0.22 | |
Payables turnover | 0.87 | 1.18 | 0.87 | 0.89 | 0.56 | |
Inventory turnover | 0.8 | 1.43 | 0.95 | 1.27 | 0.67 | |
ROE | 0.02 | -0.01 | 0.04 | 0.23 | 0.05 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
000806.SZ Frequently Asked Questions
What is Galaxy Biomedical Investment Co., Ltd. stock symbol ?
Galaxy Biomedical Investment Co., Ltd. is a CN stock and trading under the symbol 000806.SZ
What is Galaxy Biomedical Investment Co., Ltd. stock quote today ?
Galaxy Biomedical Investment Co., Ltd. stock price is $- today.
Is Galaxy Biomedical Investment Co., Ltd. stock public?
Yes, Galaxy Biomedical Investment Co., Ltd. is a publicly traded company.